Royalty Pharma PLC (NAS:RPRX)
$ 26.6 0.31 (1.18%) Market Cap: 11.82 Bil Enterprise Value: 17.66 Bil PE Ratio: 10.43 PB Ratio: 1.73 GF Score: 79/100

Royalty Pharma PLC at Evercore ISI HealthCONx Conference (Virtual) Transcript

Nov 30, 2022 / 03:30PM GMT
Release Date Price: $43.97 (+2.09%)
Umer Raffat
Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research

Thank you, guys, for joining us. Royalty Pharma management with us really excited, but I'll turn it over to Pablo and Terry to maybe kick things off, and we'll jump right in.

Pablo Legorreta
Royalty Pharma plc - Founder, Chairman of the Board & CEO

Sure. Thank you Umer for the invitation to join you this morning. And I thought it made sense just for me to spend a few minutes talking about why we're so excited about our business, the current situation we're in, in this interesting market for us. And as you mentioned, with me is Terry Coyne, our Chief Financial Officer. So I'll just start by providing some perspective on Royalty Pharma. We are the leader in the biopharma royalty market. We own a portfolio of about 45 approved and development stage products. Looking at sort of the recent financial performance, we've delivered 18% of top line growth this year. And this is a bit higher than the 13% Adjusted Cash Receipts compound annual growth

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot